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ABSTRACT
Background: Acute coronary syndromes (ACS) have
been associated with lower health utilities (HUs)
compared with the general population. Given the
prognostic improvements after ACS with the
implementation of coronary angiography
(eg, percutaneous coronary intervention (PCI)),
contemporary HU values derived from patient-reported
outcomes are needed.
Methods: We analysed data of 1882 patients with ACS
1 year after coronary angiography in a Swiss
prospective cohort. We used the EuroQol five-
dimensional questionnaire (EQ-5D) and visual analogue
scale (VAS) to derive HU indexes. We estimated the
effects of clinical factors on HU using a linear
regression model and compared the observed HU with
the average values of individuals of the same sex and
age in the general population.
Results: Mean EQ-5D HU 1-year after coronary
angiography for ACS was 0.82 (±0.16) and mean VAS
was 0.77 (±0.18); 40.9% of participants exhibited the
highest utility values. Compared with population
controls, the mean EQ-5D HU was similar (expected
mean 0.82, p=0.58) in patients with ACS, but the mean
VAS was slightly lower (expected mean 0.79, p<0.001).
Patients with ACS who are younger than 60 years had
lower HU than the general population (<0.001). In
patients with ACS, significant differences were found
according to the gender, education and employment
status, diabetes, obesity, heart failure, recurrent
ischaemic or incident bleeding event and participation
in cardiac rehabilitation (p<0.01).
Conclusions: At 1 year, patients with ACS with
coronary angiography had HU indexes similar to a
control population. Subgroup analyses based on
patients’ characteristics and further disease-specific
instruments could provide better sensitivity for detecting
smaller variations in health-related quality of life.
INTRODUCTION
Acute coronary syndromes (ACS) remain
one of the leading causes of mortality and
morbidity in European countries.1 The
implementation of recommended therapies,
such as percutaneous coronary intervention
KEY QUESTIONS
What is already known about this subject?
▸ Acute coronary syndromes (ACS) remain one of the
leading causes of mortality and morbidity in
European countries. The implementation of recom-
mended therapies, such as percutaneous coronary
intervention, effective pharmacological agents and
cardiac rehabilitation programs have considerably
reduced the incidence of major adverse cardiac and
cerebrovascular event. However, patients with ACS
may suffer from limitations in physical and func-
tional activities impacting on health utility.
What does this study add?
▸ The main results in the present study were that
health utility values measured with the EuroQol
questionnaire five dimensions (EQ-5D) in ACS
patients referred for coronary angiography were
similar to the general population, while self-rated
health status measured by visual analog scale was
significantly lower. Impact of ACS on health utility
and self-reported health status was especially pro-
nounced in patients with premature ACS.
Significant differences of health utility were found
according to gender, education, employment
status, and presence of diabetes, obesity, heart
failure, recurrent ischemic or incident bleeding
events and attendance to cardiac rehabilitation.
These findings could potentially strengthen utility
estimates (i.e. model input parameters) and update
further cost-effectiveness analyses on coronary
procedures, particularly if health utility estimates
are required for specific subgroups of ACS
patients.
How might this impact on clinical practice?
▸ Our results suggest that EQ-5D health utility values
are not lower in ACS patients referred for coronary
angiography compared to the general population,
except for patients with premature ACS. This study
shows the favorable impacts of contemporary ACS
management, including percutaneous coronary
intervention or cardiac rehabilitation, but also the
dramatic impact of premature ACS. During the
follow-up, patients who presented adverse events
after ACS (recurrence of ischemic or bleeding
events) have significantly lower health utility, as
well as those with lower educational status.
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(PCI), effective pharmacological agents and cardiac
rehabilitation (CR) programmes have considerably
reduced the incidence of major adverse cardiac and
cerebrovascular events (MACCE).2 Patients with ACS
may suffer from limitations in physical and functional
activities impacting on their health utility (HU).3 4
HU is a driving parameter in health economic studies
guiding clinical and policy decision-making.5 Indeed,
integrating HU into medical decisions or treatment
outcome is recommended by the European guidelines
for ACS management.6 The EuroQol ﬁve-dimensional
questionnaire (EQ-5D) is a common framework used to
translate different dimensions of health-related quality
of life into a single HU value. Previous studies using
EQ-5D HU have shown lower HU in patients with coron-
ary artery disease (CAD), especially in socioeconomically
vulnerable patients.3 7 8 Information about the average
HU values and their determinants in patients with ACS
are often used in economic evaluation studies on ACS.
However, a review of cost-effectiveness analyses found
that 77% of studies did not incorporate community-
based preferences and 33% used arbitrary expert elicit-
ation.7 Recent cost-effectiveness studies in coronary
patients were based on HU values (eg, quality-adjusted
life-years) from the 1990s when the PCI was less fre-
quently used than today.9 10 In this study, we aimed to
assess contemporary HU in a prospective cohort of
patients with ACS and compare the values with those of
the general population localised in the same region.11
METHODS
Study population with ACS
The Multi-dimensional Prevention Programme after Acute
Coronary Syndrome (ELIPS, study identiﬁer
NCT01075867) is a prospective cohort of patients enrolled
with a main diagnosis of ACS in four Swiss University
Hospitals (Bern, Geneva, Lausanne and Zürich).12 13 The
cohort includes patients referred for coronary angiography
between September 2009 and December 2012.14 Exclusion
criteria comprised index revascularisation with coronary
artery bypass graft (CABG), inability to give informed
consent and life expectancy <1 year (for non-cardiac
reasons). The study protocol was approved by the local
ethics committees, and all participants provided written
informed consent.
Data collection
Participants were contacted by a trained study nurse for
a clinical visit 1 year after the ACS at the enrollment site.
If patients were unable to attend the consultation per-
sonally, the data collection was performed in the follow-
ing order: (1) over the phone, (2) by mail or email, (3)
through family members and ﬁnally (4) through the
primary care physician. We collected baseline data on
sociodemographic characteristics, cardiovascular history,
cardiovascular risk factors, cardiovascular medication
and participation in cardiac rehabilitation (CR). During
the follow-up visit, we assessed the incidence of MACCE,
such as the overall mortality, recurrence of myocardial
infraction (MI), stroke, hospitalisation for unstable
angina and peripheral artery disease. We also collected
data on bleeding events using the standardised deﬁn-
ition.15 All events were adjudicated by a panel of certi-
ﬁed cardiologists, based on the medical records.
Measurement of HU
HU in the ELIPS cohort was measured using the vali-
dated EQ-5D questionnaire during the 1-year follow-up
visit. In addition, the instrument includes a VAS, repre-
sented by a vertical scale. The EQ-5D questionnaire con-
sists of ﬁve questions, each representing one dimension.
These ﬁve dimensions are mobility, self-care, usual activ-
ities, pain, discomfort, anxiety and depression. For each
dimension, participants were asked to report their status
on a three-level ordinal scale: no problems, some pro-
blems or severe problems. Health states among the 243
possible combinations from the EQ-5D questionnaire
index were translated to HU index for each respondent
using a standard pan-European value set.16 HU is mea-
sured on a scale between 0 and 1, 1 representing perfect
health and 0 representing death. To compare the esti-
mates of HU in our cohort with those obtained in the
general population, we used the previously published
reference values from among the 1952 randomly
selected adults in the French-speaking part of
Switzerland.11
Statistical analysis
The primary end point was the EQ-5D-derived HU
index and self-rated health status using VAS results
1 year after hospitalisation for ACS. We presented the
frequency distributions of the EQ-5D items and
the mean values and SDs of HU and VAS results. The
average HU and VAS results were presented for different
clinically relevant subgroups.6 We used χ2 tests for
dichotomous outcomes and t-tests for continuous out-
comes. A multiple linear regression model was estimated
to study the association between HU and VAS values and
patient characteristics (age, sex, education and working
status), clinical parameters (body mass index (BMI), dia-
betes, hypertension, signs of heart failure (HF), heart
rate, type of ACS), CR and the occurrence of adverse
events deﬁned by the combination of MACCE or bleed-
ing events. The selection of variables was deﬁned prior
to the statistical analysis and was based on clinical judg-
ment and previous publication.17 Age was categorised
into the following groups:<50, 50–59, 60–69, 70–79
and≥80 years old as performed in a previous publication
on the general population;11 BMI into three categories
of normal weight (<25 kg/m2), overweight (25–29.9 kg/
m2) and obesity (≥30.0 kg/m²); heart rate estimated
were presented for an increase of each 10 bpm. The
individual outcomes of HU and VAS in the surveyed
patients with ACS 1 year after coronary angiography
were compared with the predicted values of these
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patients if they were average members of the general
population. The predicted values of identical individuals
in the general population were calculated using a pub-
lished prediction equation estimated for Switzerland.11
The prediction equations included age, age squared and
sex: HU=0.84822−0.00208×(age−50)−0.00002×(age−50)2
−0.02090 if female for EQ-5D utilities and VAS=83.183
−0.199×(age−50)−0.006×(age−50)2+0.401 if female for
VAS self-assessed utilities. These equations allow the
computation of individual expected values without the
problems posed by small samples within strata and by dis-
crete jumps between strata. We reported the differences
of the observed minus predicted outcomes of the mean
EQ-5D HU and VAS and then used a parametric
one-sample t-test.
RESULTS
Baseline characteristics
Of the 2352 patients enrolled at baseline for angiog-
raphy during the index ACS event from September 2009
to December 2012, 50 (2.2%) died; 49 (2.1%) refused
the follow-up; 41 were lost to follow-up (1.7%); 84
(3.6%) had a follow-up beyond 450 days and 245
(11.2%) had missing data for fully completed EQ-5D
items, yielding to a ﬁnal sample of 1882 participants for
primary analysis. Mean age was 62.0 (11.8); 79.8% were
men; 16.6% had diabetes; 53.6% had hypertension;
20.8% were obese and 1308 (70.6%) attended a CR pro-
gramme after hospital discharge (table 1).
Description of HU
In the overall ACS study population, the mean EQ-5D was
0.82 (0.16) for HU and VAS was 0.77 (0.17) (table 2).
It has been estimated that 40.9% of all patients with
ACS reported the highest utility values in all ﬁve EQ-5D
dimensions; 16.3% of patients with ACS had problems
with mobility, 3.5% with self-care, 15.9% with daily activ-
ities, 45.8% had pain or discomfort and 33.0% suffered
from anxiety or depression (table 2). The highest bound
of VAS was lower among patients who reported the
highest utilities in all ﬁve EQ-5D dimensions compared
with HU (0.86 vs 0.98, p<0.001).
Clinical characteristics of patients with ACS and HU at
1 year
In subgroup analyses, we found that HU (0.83 vs 0.77,
p<0.001) and VAS (0.77 vs 0.73, p<0.001) at 1 year were
signiﬁcantly lower in women (table 2). Patients who
attended a CR programme after hospital discharge
reported signiﬁcantly higher HU (0.83 vs 0.79, p<0.001)
and VAS (0.74 vs 0.78, p<0.001) 1 year after ACS, while
patients who presented the occurrence of MACCE or a
bleeding event after the index ACS reported lower HU
(0.78 vs 0.82, p<0.001) and VAS (0.71 vs 0.77, p<0.001)
at 1 year. The multivariate linear regression model sug-
gested that women, low educational status, unemploy-
ment or retired status, patients with obesity, diabetes,
hypertension, heart failure symptoms and persisting ele-
vated heart rate are signiﬁcant predictors of low HU and
VAS self-rated health status 1 year after ACS (table 3). In
addition, patients who presented MACCE or bleeding
events during the year (from baseline to the 1-year
follow-up) experienced an additional decrement in their
HU at 1 year. On the contrary, attendance to a CR pro-
gramme after hospital discharge was associated with sig-
niﬁcantly higher HU. The coefﬁcients of the
multivariable model were similar both for EQ-5D HU
and VAS outcomes.
Table 1 Baseline characteristics of 1882 patients with
ACS referred for coronary angiography in four Swiss
Academic Centers
Demographics
Age, mean (±SD) 62.0 (11.8)
Male 1501 (79.8)
University education, 284 (15.5)
Married or partnership 1274 (67.8)
No employment or retired 899 (48.1)
Living with someone 1445 (76.9)
CVRF or medical history
BMI (kg/m2) categories, n (%)
<25 kg/m² 600 (32.3)
25.0–29.9 kg/m² 865 (78.9)
≥30.0 kg/m² 392 (21.1)
Current smoking 748 (39.7)
Diabetes 313 (16.6)
Hypercholesterolaemia 1146 (61.0)
Hypertension 1009 (53.6)
Previous MI 269 (14.3)
Hospitalisation data
ACS diagnosis
Unstable angina, n (%) 84 (4.5)
NSTEMI, n (%) 746 (39.6)
STEMI, n (%) 1052 (55.9)
Index revascularisation
PCI with stent 1642 (87.3)
PCI with balloon 100 (5.3)
Conservative 140 (7.4)
Killip classification
Killip 1 1675 (89.9)
Killip 2 131 (7.0)
Killip 3 25 (1.3)
Killip 4 32 (1.7)
Discharge data
Attendance to CR, n (%) 1308 (70.6)
Documentation of aspirin, n (%) 1881 (100)
Documentation of P2Y12 inhibitors
if PCI, n (%)
1684 (99.5)
Documentation of statin, n (%) 1861 (98.9)
Documentation of β-blocker, n (%) 1764 (93.7)
Documentation of ACEI/ARB, n (%) 1875 (99.6)
ACS, acute coronary syndromes; ACEI, ACE inhibitors; ARB,
angiotensin receptor blocker; BMI, body mass index; CABG,
coronary artery bypass grafting; CR, cardiac rehabilitation; CVRF,
cardiovascular risk factor; EQ-5D, EuroQol five-dimensional
questionnaire; Killip, MI, myocardial infarction; NSTEMI,
Non-ST-elevation myocardial infarction; PCI, percutaneous
coronary intervention; STEMI, ST-elevation myocardial infarction;
UA, unstable angina.
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Table 2 Subgroup comparisons of the EQ-5D questionnaires in 1882 patients 1 year after coronary angiography for ACS
Total
Number
EQ-5D Health
Utility
Visual analogue
scale
Some or severe
problem with
mobility
Some or severe
problem with
self-care
Some or severe
problem with
daily activities
Some or severe
problem with
pain/discomfort
Some or severe
problem with
anxiety/depression
Mean (SD) Mean (SD) (%) (%) (%) (%) (%)
Total 1882 0.82 (0.16) 0.77 (0.17) 16.3 3.5 15.9 45.8 33.0
Sex p<0.001 p<0.001 p<0.001 p=0.03 p<0.001 p<0.001 p=0.001
Women 381 0.77 (0.16) 0.73 (0.18) 24.4 5.3 22.3 56.4 42.5
Men 1501 0.83 (0.16) 0.77 (0.17) 14.2 3.0 14.9 43.0 30.9
Age group (years) p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 p<0.001
<50 309 0.83 (0.17) 0.78 (0.19) 10.0 1.6 14.6 36.6 38.8
50-59 522 0.81 (0.17) 0.7 (0.17) 12.6 3.1 18.1 46.0 39.7
60-69 550 0.84 (0.15) 0.79 (0.16) 14.9 3.3 12.4 41.6 28.2
70-79 365 0.81 (0.16) 0.75 (0.18) 19.7 3.6 12.6 49.9 27.1
≥80 136 0.74 (0.15) 0.69 (0.19) 40.4 9.6 33.8 71.3 33.1
Education p<0.001 p<0.001 p=0.006 p<0.001 p=0.001 p<0.001 p=0.012
Basic 348 0.77 (0.17) 71.9 (18.5) 21.3 8.0 22.7 56.6 42.2
Vocational 963 0.82 (0.16) 76.5 (17.4) 16.5 2.2 15.9 48.1 31.9
High school 243 0.83 (0.17) 79.1 (16.7) 11.9 3.3 12.8 38.3 32.5
University 284 0.84 (0.16) 79.0 (16.2) 13.7 2.1 11.6 33.8 29.9
Working p<0.001 p<0.001 p<0.001 p<0.001 p=0.013 p<0.001 p=0.216
Full time 800 0.84 (0.15) 0.79 (0.16) 8.4 1.0 12.6 37.5 32.6
Part time 170 0.79 (0.16) 0.76 (0.16) 17.1 2.9 16.5 50.0 40.6
None/retired 899 0.80 (0.17) 0.74 (0.19) 23.1 5.8 18.7 52.4 32.4
Diabetes p<0.001 p<0.001 p<0.001 p<0.001 p=0.002 p<0.001 p=0.100
Yes 313 0.78 (0.19) 0.72 (0.19) 25.2 8.6 22.0 55.0 38.0
No 1569 0.82 (0.16) 0.77 (0.17) 14.5 2.4 14.7 43.9 32.3
Hypertension p<0.001 p<0.001 p<0.001 p=0.004 p=0.001 p=0.001 p=0.318
Yes 1009 0.80 (0.17) 0.75 (0.18) 20.4 4.8 19.6 51.6 34.8
No 873 0.84 (0.16) 0.79 (0.16) 11.5 1.9 11.6 38.9 31.5
ACS diagnosis p=0.002 p<0.001 p=0.006 p=0.538 p=0.833 p=0.003 p=0.276
Unstable angina 84 0.78 (0.18) 0.74 (0.17) 29.8 4.7 11.9 58.3 43.2
NSTEMI 746 0.80 (0.16) 0.74 (0.18) 15.5 3.9 16.1 49.3 34.6
STEMI 1052 0.83 (0.16) 0.78 (0.17) 15.7 3.0 16.1 42.2 32.0
BMI p<0.001 p<0.001 p<0.001 p=0.002 p=0.003 p<0.001 p=0.139
Normal 600 0.82 (0.16) 0.78 (0.17) 14.7 3.8 14.3 45.3 32.2
Overweight 865 0.82 (0.16) 0.77 (0.17) 13.6 2.1 14.5 42.4 33.3
Obese 392 0.78 (0.18) 0.73 (0.19) 24.0 6.1 21.9 54.8 34.9
HF at baseline p<0.001 p<0.001 p<0.001 p<0.001 p<0.001 p=0.009 p=0.129
Killip 1 1675 0.83 (0.16) 0.77 (0.17) 15.1 2.8 14.7 44.8 32.7
Killip 2-4 188 0.76 (0.18) 0.72 (0.20) 27.1 9.6 26.1 54.8 39.9
Cardiac Rehabilitation p<0.001 p<0.001 p<0.001 p<0.001 p=0.038 p<0.001 p=0.673
Yes 1308 0.83 (0.16) 0.78 (0.17) 13.2 2.3 15.0 41.7 33.8
No 545 0.79 (0.18) 0.74 (0.19) 23.1 6.4 18.7 55.4 31.7
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Comparison of HU with the general population
We did not ﬁnd signiﬁcant differences between the
average HU in the patient with ACS cohort and the
average predicted values from the equation of the
general population (0.82 vs 0.82, p=0.577) (table 4). No
differences were found according to sex, but HU was sig-
niﬁcantly lower in patients with ACS younger than
60 years (−0.03, p<0.001) compared with the control
groups. Regarding self-rated health status, we found sig-
niﬁcant differences between the observed and predicted
values of VAS (0.76 vs 0.79, p<0.001), especially in
patients younger than 60 years old (−0.06, p<0.001).
DISCUSSION
The main results in this study were that HU values in
patients with ACS referred for coronary angiography
were similar to the general population, while self-rated
health status measured by VAS was signiﬁcantly lower.
The impact of ACS on HU and self-reported health
status was especially pronounced in patients younger
than 60 years old. Signiﬁcant differences of HU were
found according to gender, education, employment
status, presence of diabetes, obesity, heart failure, recur-
rent ischaemic or incident bleeding events and attend-
ance to cardiac rehabilitation. These ﬁndings could
potentially strengthen utility estimates (ie, model input
parameters) and update further cost-effectiveness ana-
lyses on coronary procedures, particularly if HU and
quality-of-life estimates are required for speciﬁc sub-
groups of patients with ACS.
A wide range of HU instruments yield various score
amplitudes and discriminate more precisely the treat-
ment differences. In the 1 -year results of the third
Randomised Intervention Trial of unstable Angina
(RITA-3), VAS scores were better for interventional strat-
egy than for conservative at 4 months (treatment differ-
ence of 3.0, p<0.001) and 1 year (2.3, p<0.01) and the
EQ-5D utility scores were less statistically signiﬁcant at
4 months (treatment difference: 0.036, p<0.01) and not
signiﬁcant at 1 year (0.016, p=0.20).18 Although the ease
of VAS use also provides information on patients’ global
state of well-being and allows comparability of relative
health state across various illnesses, other disease-speciﬁc
instruments would provide greater sensitivity for detect-
ing the tiny variations in quality-of-life estimates and
information on the inﬂuence of various factors on
HU.19 20
Further patient-reported outcome studies could
conﬁrm the important issue of whether or not the dis-
utility due to ACS differs signiﬁcantly across subgroups.
These speciﬁcities are scantly reported in cost-
effectiveness analyses and clinical trials, although differ-
ences of health status were observed according to vulner-
ability in patients with CAD.3
In the multivariate analysis, attendance to cardiac
rehabilitation was signiﬁcantly associated with higher
estimates of HU. This result is in line with ﬁndings from
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previous studies showing that good medication compli-
ance, regular physical activity, risk factor modiﬁcation
and patient-centered care are associated with higher
HU.17 Indeed, randomised controlled trials in patients
with ACS do generally not report the rates of CR attend-
ance. We also observed that obesity, diabetes and factors
of poor adherence to a healthy lifestyle were associated
with lower HU. At the time of inclusion, about 10% of
participants had signs of HF. In the multivariate model,
HF signs and persisting elevated heart rate were signiﬁ-
cantly associated with poorer HU and self-reported
health status. Since it is likely that patients with decom-
pensate HF are under-represented in clinical trials (eg,
in PLATO trial, 1% of patients had Killip >2 at the inclu-
sion), these patient-reported outcome added valuable
information on real-life representation after ACS.21
Regarding gender issue, in a recent cohort of patients
with premature ACS, women reported worse HU than
men in the domain of physical and mental functioning,
suggesting that cultural and social role of women could
have a negative impact on HU.22 In our study, the lower
HU in women remained present and statistically signiﬁ-
cant even after adjustment for clinical variables.
Regarding socioeconomic factors, we found that patients
with lower education and employment had worse EQ-5D
HU.
Recent cost-effectiveness studies assessing the revascu-
larisation strategies in patients with CAD derived esti-
mates from data published in the 1990s.9 23 In the USA,
reference values for patients with CAD were deﬁned as a
Table 3 Multivariate model of associated factors with health utility and self-rated health status in 1882 patients 1 year after
coronary angiography for ACS
Variables
EQ-5D health utility VAS
Coefficient p Value Coefficient p Value
Sociodemographics
Age categories (years old)
<50 Ref
50–59 −0.007 0.566 −0.007 0.5622
60–69 0.050 <0.001 0.063 <0.001
70–79 0.050 0.002 0.058 0.001
>80 0.003 0.878 0.12 0.576
Women −0.026 0.016 −0.014 0.205
BMI categories
Normal (<25.0 kg/m2) Ref Ref
Overweight (25.0–29.9 kg/m2) 0.002 0.866 −0.006 0.533
Obese (≥30.0 kg/m2) −0.034 0.002 −0.038 0.001
Education level
Lower than vocational Ref Ref
Vocational 0.031 0.004 0.033 0.003
High school 0.037 0.008 0.050 0.001
University 0.043 0.002 0.042 0.004
Working status
Full time Ref
Part time −0.039 0.007 −0.022 0.156
No employment/retired −0.045 <0.001 −0.050 <0.001
Medical conditions at baseline
History of diabetes −0.029 0.007 −0.035 0.005
History of hypertension −0.021 0.012 −0.171 0.058
ACS diagnosis
Unstable angina Ref Ref
NSTEMI 0.023 0.237 −0.010 0.645
STEMI 0.029 0.148 0.005 0.808
Baseline heart failure
Killip 1 Ref Ref
Killip 2-4 0.043 0.001 0.042 0.002
Preventive intervention
Cardiac rehabilitation 0.022 0.018 0.023 0.020
One-year outcomes
MACCE or bleeding events −0.031 0.005 −0.048 <0.001
Heart rate at 1 year (per 10 bpm at rest) −0.009 0.017 −0.012 0.002
ACS, acute coronary syndromes; BMI, body mass index; CABG, coronary artery bypass graft; EQ-5D, EuroQol five-dimensional
questionnaire; MACE, major adverse cardiac and cerebrovascular events; NSTEMI, non-ST-elevation myocardial infarction; PCI,
percutaneous coronary intervention; Ref, reference; STEMI, ST-elevation myocardial infarction; VAS, visual analogue scale.
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mean value of 0.70 for EQ-5D.7 In a German registry of
patients with MI, the reported mean EQ-5D was 0.87
(0.15), while the VAS was 0.66 (0.19).4 The variability of
the EQ-5D HU across studies could be explained by dif-
ferent adaptations from EQ-5D into an aggregated HU
value and by patient’s characteristics. Prognosis of the
ACS population has considerably improved with the use
of PCI, and with the use of more effective pharmaco-
logical agents, such as statins and potent P2Y12 inhibi-
tors.6 Particularly, a cost-effectiveness analysis of
clopidogrel was limited due to the absence of reliable
estimates for HU in patients with ACS.10 This is espe-
cially important given that a reduction of 0.1 of HU in a
sensitivity analysis could potentially change the cost-
effectiveness ratios in patients with ACS.10 In the
PLATelet inhibition and patient Outcomes (PLATO)
trial, cost-effectiveness analysis of the ticagrelor strategy
versus clopidogrel strategy used a mean QALY of 0.846
in patients with ACS based on EQ-5D instrument.4 5
Parameters for long-term extrapolation considered a
QALY decrement of 0.075 for recurrent non-fatal MI
and a decrement of 0.103 for non-fatal stroke.6 The
adjustment according to age considered an estimate of
0.874 for those <69 years, 0.813 for those 70–79 years
and 0.754 for those >79 years.23 24 However, those ana-
lyses did not speciﬁcally adapt HU estimates for import-
ant subgroups, such as diabetes, type of ACS, HF,
education or attendance to CR.4 7
Strengths are the prospective nature of the study, the
large number of patients with >80% HU follow-up rate
at 1 year, and the global assessments between patients’
characteristics and HU.
Our study has several limitations. We measured HU by
means of validated, but already existing simple assess-
ment tools, such as EQ5D and VAS, but other
concomitant questionnaires (eg, SF-36) or new assess-
ment tools speciﬁcally designed for patients with ACS
might have strengthened the ﬁndings. For instance, our
data did not ﬁnd signiﬁcant differences of EQ-5D HU in
patients with ACS compared with the general population
in Switzerland, except for patients younger than 60 years
old. One potential explanation is the favourable impact
of modern therapies on the prognosis of ACS; an alter-
nate hypothesis might be the lack of sensitivity of the
EQ-5D HU to detect differences due to ceiling effects.11
Although we applied an equation based on age and
gender developed in the general population to predict
expected HU in the control group, the ACS cohort was
different in terms of baseline characteristics (eg, higher
proportion of women in the control group compared
with the ACS population).
EQ-5D has been reported to be valid and reliable in
patients with CAD.8 The EQ-5D HU is able to detect
clinical symptoms, such as severe angina or HF symp-
toms, and has been validated with disease-speciﬁc instru-
ment, such as the Seattle Angina Questionnaire. We
have previously reported that an HU assessment limited
to ﬁve dimensions may miss important health issues in a
large proportion of individuals.28 The addition of ﬁve
alternative health dimensions (sleep, memory/concen-
tration, fatigue/energy, sight/hearing and contact with
others) was able to improve the variance of health status
expressed in VAS.28 Nevertheless, EQ-5D was able to
detect in our study the greater impact of ACS conﬁrm-
ing the important effect of premature ACS on productiv-
ity and opportunity costs in younger patients.29
Self-reported health status measured by VAS has been
used in large cardiovascular studies, such as the Bypass
Angioplasty Revascularization Investigation 2 Diabetes.30
Some data suggest that self-rated health status is not only
Table 4 Differences between observed and predicted mean values of health utility and self-reported health status. In 1882
patient 1 year after coronary angiography for ACS
EQ-5D health utility Visual analogue scale
Differences
observed-predicted*
Mean (SD) p Value†
Differences
observed-predicted‡
Mean (SD) p Value
Total 0.00 (0.16) 0.577 −0.03 (0.18) <0.001
Sex
Women −0.01 (0.17) 0.281 −0.05 (0.18) <0.001
Men 0.00 (0.16) 0.235 −0.02 (0.18) <0.001
Age group (years)
<50 −0.03 (0.17) 0.004 −0.06 (0.19) <0.001
50–59 −0.03 (0.17) <0.001 −0.07 (0.17) <0.001
60–69 0.03 (0.15) <0.001 0.00 (0.16) 0.503
70–79 0.04 (0.16) <0.001 0.01 (0.18) 0.594
≥80 0.00 (0.15) 0.751 −0.00 (0.19) 0.791
*The predicted equation for EQ-5D health utility was derived from the general population 0.84822−0.00208× (age−50)−0.00002×
(age−50)2−0.02090 if women.
†p Value was obtained using one sample t-test.
‡The predicted equation for VAS was 83.183−0.199 (age−50)−0.006 (age−50)2+0.401 if women.
ACS, acute coronary syndromes; EQ-5D, EuroQol five-dimensional questionnaire; PCI, percutaneous coronary intervention; VAS, visual
analogue scale.
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a spontaneous assessment of one’s health status, but a
marker of achievement of one’s relatively important
health-related goals.31 This might be particularly import-
ant in younger patients who tend to evaluate their
health state more negatively. In addition, a subjective
evaluation of the health status in patients with ACS
could be additionally inﬂuenced by socioeconomic or
psychological factors beyond standardised preferences of
the EQ-5D instrument. Health economic studies are
usually based on HU indexes derived from generic
instruments, such as EQ-5D, while estimates derived
from the VAS are more rarely used.9 Our data suggest
that VAS could be more sensitive to detect differences of
health loss in patients with ACS, compared with the
EQ-5D instrument. In addition, our data suggest that
aggregated estimates for health utility can miss import-
ant information emphasising the need of subgroup and
scenario analyses.
Another limitation remains in the fact that our sample
might not represent all patients who survived after ACS
(selection bias). Indeed, not all individuals with cardio-
genic shock or after resuscitation had been included in
all centres, explained by the low mortality rate in the
entire cohort. However, the mean age of patients
included in our cohort was similar to another Swiss
registry of patients with ACS, and also to the proportion
of patients with heart failure at baseline.32 Although we
applied an equation from the Swiss general population
based on age and sex, it might be possible that differences
between observed and predicted values were not only
explained by ACS (eg, effect of smoking or low physical
activity more prevalent in patients with ACS) leading to
an overestimation of disutility of ACS. Thus, in the healthy
control population cohort, there were 56% women,
whereas in the patients’ groups, 79.8% were men.
Conclusion
Our results suggest that EQ-5D health utility values are
not signiﬁcantly lower in patients with ACS referred for
coronary angiography compared with the general popu-
lation. Possibly, the EQ-5D instrument focusing on ﬁve
dimensions does not capture the health utility accurately
enough or, alternatively, it showed favourable impacts of
contemporary ACS management more rapidly than
global self-reported health utility. In contrast, if VAS
detects signiﬁcant differences of aggregated health
utility values, it might be a more appropriate instrument
in ACS patients. In addition, our study emphasises the
relevance of patients’ characteristics in the estimation of
speciﬁc health utility indexes. Future patient-reported
outcomes and health economic studies on ACS should
address these patients’ heterogeneity issues using sub-
groups, scenario and sensitivity analyses with probabilis-
tic approaches to further reduce parameter uncertainty.
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